In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression

Viral Immunology

Volumn 25, Issue 1, 2012, Pages 45-54

  Kurle, Swarali ^a   Thakar, Madhuri ^a   Shete, Ashwini ^a   Paranjape, Ramesh ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESPONSE; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; NUCLEOTIDE SEQUENCE;

AIDS VACCINES; ANTIGEN-PRESENTING CELLS; CYTOKINES; DENDRITIC CELLS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA;

EID: 84856703490     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0055     Document Type: Article

References (54)

1. Akondy RS, Monson ND, Miller JD, et al.: The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009;183:7919-7930.
2. Betts MR, Exley B, Price DA, et al.: Characterization of functional and phenotypic changes in anti-Gag vaccineinduced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005;102:4512-4517. (Pubitemid 40397143)
3. Betts MR, Nason MC, West SM, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 + T cells. Blood 2006;107:4781-4789. (Pubitemid 43882629)
4. Billaud J., Yagello M, and Gluckman JC: Primary in vitro sensitization of human T-helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein. Vaccine 1994;12:46-55.
5. Boczkowski D, Nair SK, Snyder D, and Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472. (Pubitemid 26324100)
6. Bonini C, Lee SP, Riddell SR, and Greenberg PD: Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4 + and CD8 + T cells. J Immunol 2001;166:5250-5257. (Pubitemid 32280742)
7. Churchyard GJ, Morgan C, Adams E, et al.: A Phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;6:e21225.
8. Cohen J: AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007;318:1048-1049. (Pubitemid 350134865)
9. Darrah PA, Patel DT, De Luca PM, et al.: Multifunctional Th1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-850. (Pubitemid 47038186)
10. DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, and Seigler H: Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998;68:79-91. (Pubitemid 28269975)
11. Fauce SR, Yang OO, and Effros RB: Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. J Immunol Methods 2007;327:75-81. (Pubitemid 47444313)
12. Ferre AL, Hunt PW, Critchfield JW, et al.: Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009;113:3978-3989.
13. Ferre AL, Hunt PW, McConnell DH, et al.: HIV controllers with HLA-DRB11 3 and HLA-DQB1 06 alleles have strong, polyfunctional mucosal CD4 + T-cell responses. J Virol 2010;84:11020-11029.
14. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, and Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
15. Gaucher D, Therrien R, Kettaf N, et al.: Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008;205:3119-3131.
16. Gomez CE, Perdiguero B, Garcia-Arriaza J, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011;Epub ahead of print.
17. Gray D, and Matzinger P: T cell memory is short-lived in the absence of antigen. J Exp Med 1991;174:969-974.
18. Harari A, Bart PA, Stohr W, et al.: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77. (Pubitemid 351185716)
19. Harari A, Petitpierre S, Vallelian F, and Pantaleo G: Skewed representation of functionally distinct populations of virus- specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-972. (Pubitemid 38129558)
20. Heinzel S, Rea D, Offringa R, and Pawelec G: The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4 + T lymphocytes to recognize melanoma cells. Cancer Immunol Immunother 2001;49:671-678. (Pubitemid 32656628)
21. Inaba K, Metlay JP, Crowley MT, and Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-640. (Pubitemid 20248404)
22. Johnston MI, and Fauci AS: An HIV vaccine-evolving concepts. N Engl J Med 2007;356:2073-2081.
23. Koup RA, Roederer M, Lamoreaux L, et al.: Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5:e9015.
24. Kurle S, Tripathy S, Jadhav S, Agnihotri K, and Paranjape R: Full-length gag sequences of HIV type 1 subtype C recent seroconverters from Pune, India. AIDS Res Hum Retroviruses 2004;20:1113-1118. (Pubitemid 39392016)
25. Lanzavecchia A, and Sallusto F: Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000;290:92-97.
26. Lanzavecchia A, and Sallusto F: Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-332. (Pubitemid 40692670)
27. Larsson M, Wilkens DT, Fonteneau JF, et al.: Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS 2002;16:171-180. (Pubitemid 34118563)
28. Letvin NL, Mascola JR, Sun Y, et al.: Preserved CD4 + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006;312:1530-1533. (Pubitemid 43865893)
29. Li W, Li S, Hu Y, Tang B, Cui L, and He W: Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine 2008;26:3282-3290.
30. Lindenstrom T, Agger EM, Korsholm KS, et al.: Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009;182:8047-8055.
31. Lisziewicz J, Gabrilovich DI, Varga G, et al.: Induction of potent human immunodeficiency virus type 1-specific T-cellrestricted immunity by genetically modified dendritic cells. J Virol 2001;75:7621-7628. (Pubitemid 32738020)
32. Macatonia SE, Patterson S, and Knight SC: Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 1991;74:399-406.
33. Meddows-Taylor S, Shalekoff S, Kuhn L, Gray GE, and Tiemessen CT: Development of a whole blood intracellular cytokine staining assay for mapping CD4( + ) and CD8( +) Tcell responses across the HIV-1 genome. J Virol Methods 2007;144:115-121. (Pubitemid 47103224)
34. Moser JM, Sassano ER, Leistritz del C, Eatrides JM, Phogat S, Koff W, and Drake DR 3rd: Optimization of a dendritic cellbased assay for the in vitro priming of naive human CD4 + T cells. J Immunol Methods 2010;353:8-19.
35. Mullbacher A: The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen. J Exp Med 1994;179:317-321. (Pubitemid 24012998)
36. Neitzel H: A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986;73:320-326. (Pubitemid 16047212)
37. Palmer BE, Boritz E, and Wilson CC: Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4 + T cell maturation and function. J Immunol 2004;172:3337-3347. (Pubitemid 38263726)
38. Precopio ML, Betts MR, Parrino J, et al.: Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8( + ) T cell responses. J Exp Med 2007;204: 1405-1416. (Pubitemid 46919878)
39. Ringe R, Thakar M, and Bhattacharya J: Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naive Indian patients with recent infection. Retrovirology 2010;7:76.
40. Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postol E, Kalil J, and Cunha-Neto E: A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, longlived CD4 + and CD8 + T cell responses. PLoS One 2011; 6:e16921.
41. Saez-Cirion A, Lacabaratz C, Lambotte O, et al.: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007;104:6776-6781. (Pubitemid 47175577)
42. Sallusto F, and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
43. Sallusto F, and Lanzavecchia A: Exploring pathways for memory T cell generation. J Clin Invest 2001;108:805-806. (Pubitemid 32880290)
44. Sallusto F, Lenig D, Forster R, Lipp M, and Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401: 708-712.
45. Seder RA, and Ahmed R: Similarities and differences in CD4 + and CD8 + effector and memory T cell generation. Nat Immunol 2003;4:835-842. (Pubitemid 37098653)
46. Seder RA, Darrah PA, and Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258. (Pubitemid 351432801)
47. Stockinger B, Kassiotis G, and Bourgeois C: CD4 T-cell memory. Semin Immunol 2004;16:295-303. (Pubitemid 39446557)
48. Thakar MR, Bhonge LS, Lakhashe SK, et al.: Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. J Infect Dis 2005;192:749-759. (Pubitemid 41193072)
49. Tuting T, Wilson CC, Martin DM, et al.: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998;160:1139-1147. (Pubitemid 28093408)
50. Valentin A, Chikhlikar P, Patel V, et al.: Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009;27:4840-4849.
51. Wang J, Saffold S, Cao X, Krauss J, and Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998;161:5516-5524. (Pubitemid 28519115)
52. Yoshida A, Tanaka R, Murakami T, et al.: Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4( +) Tcell origin. J Virol 2003;77:8719-8728. (Pubitemid 36936083)
53. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, and Sekaly RP: HIV-1 viremia prevents the establishment of interleukin 2-producing HIVspecific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003;198:1909-1922. (Pubitemid 38032123)
54. Zhang X, Sun S, Hwang I, Tough DF, and Sprent J: Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 1998;8:591-599. (Pubitemid 28264750)